{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:55:45Z","timestamp":1793051745523,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Immune checkpoint inhibitors have recently been widely used for advanced cancers and are known to cause ocular complications. We herein report a case developing bilateral serous retinal detachments, without ocular inflammation, after starting nivolumab treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 73-year-old man was referred to our hospital, having become aware of metamorphopsia 2 months after starting nivolumab (anti-programmed cell death protein 1 monoclonal antibody) for malignant melanoma of the nasal cavity. The initial corrected visual acuity of the right eye was 20\/20, and that of the left eye was 20\/16. There were no inflammatory findings in the anterior segment or the vitreous. Vitelliform lesions were found in the macular area of both ocular fundi, consistent with serous retinal detachment and subretinal deposits. Swept source optical coherence tomography showed diffuse thickening of the outer photoreceptor segment and thickening of the choroid. Two months after the initial diagnosis, multiple vitelliform lesions were noted, and the fundus findings had worsened. Indocyanine green fluorescein angiography showed delayed inflow in the peripapillary and posterior pole regions in the early phase of imaging. Fundus autofluorescence showed hyperautofluorescence consistent with most of the vitelliform lesions on color fundus photography.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Nivolumab may have impaired the pumping and phagocytosis functions of retinal pigment epithelial cells, resulting in bilateral serous retinal detachments and thickening of the photoreceptor outer segment. This is the first\u00a0case report, to our knowledge, describing multiple bilateral serous retinal detachments and outer segment thickening without inflammation in a patient treated with nivolumab.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01495-w","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T13:07:44Z","timestamp":1591621664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Reina","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-8893","authenticated-orcid":false,"given":"Hiroyuki","family":"Nakashizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusaburo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"Suppl 7","key":"1495_CR1","doi-asserted-by":"publisher","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","volume":"58","author":"L Spiers","year":"2019","unstructured":"Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors\u2014an overview. Rheumatology. 2019;58(Suppl 7):vii7\u201316. https:\/\/doi.org\/10.1093\/rheumatology\/kez418.","journal-title":"Rheumatology"},{"issue":"6","key":"1495_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effect. Retina. 2018;38(6):1063\u201378. https:\/\/doi.org\/10.1097\/IAE.0000000000002181.","journal-title":"Retina."},{"issue":"5","key":"1495_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5(5):694\u2013700. https:\/\/doi.org\/10.1002\/ccr3.911.","journal-title":"Clin Case Rep"},{"issue":"1","key":"1495_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, Teramura K, Ohji M. Vogt-koyanagi-harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019;10(1):67\u201374. https:\/\/doi.org\/10.1159\/000496682.","journal-title":"Case Rep Ophthalmol"},{"issue":"7","key":"1495_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.18240\/ijo.2017.07.28","volume":"10","author":"DR Richardson","year":"2017","unstructured":"Richardson DR, Ellis B, Mehmi I, Leys M. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. Int J Ophthalmol. 2017;10(7):1183\u20136. https:\/\/doi.org\/10.18240\/ijo.2017.07.28.","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"1495_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/tjo.tjo_88_17","volume":"8","author":"CJ Chang","year":"2018","unstructured":"Chang CJ, Chen SJ, Hwang DK, Liu CL. Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol. 2018;8(3):173\u20135. https:\/\/doi.org\/10.4103\/tjo.tjo_88_17.","journal-title":"Taiwan J Ophthalmol"},{"key":"1495_CR7","doi-asserted-by":"publisher","unstructured":"Zhou R, Caspi RR. Ocular immune privilege. F1000 Biol Rep. 2010;2. https:\/\/doi.org\/10.3410\/B2-3.","DOI":"10.3410\/B2-3"},{"issue":"2","key":"1495_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/ICB.0000000000000604","volume":"13","author":"HS Sandhu","year":"2019","unstructured":"Sandhu HS, Kolomeyer AM, Lau MK, Shields CL, Schuchter LM, Nichols CW, Aleman TS. Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep. 2019;13(2):103\u20137. https:\/\/doi.org\/10.1097\/ICB.0000000000000604.","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"1495_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/archophthalmol.2010.316","volume":"129","author":"L Koreen","year":"2011","unstructured":"Koreen L, He SX, Johnson MW, Hackel RE, Khan NW, Heckenlively JR. Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis. Arch Ophthalmol. 2011;129(1):23\u20139. https:\/\/doi.org\/10.1001\/archophthalmol.2010.316.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1495_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/archopht.125.2.274","volume":"125","author":"V Vaclavik","year":"2007","unstructured":"Vaclavik V, Ooi KG, Bird AC, Robson AG, Holder GE, Webster AR. Autofluorescence findings in acute exudative polymorphous vitelliform maculopathy. Arch Ophthalmol. 2007;125(2):274\u20137. https:\/\/doi.org\/10.1001\/archopht.125.2.274.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"1495_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","volume":"133","author":"D Mantopoulos","year":"2015","unstructured":"Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol. 2015;133(8):965\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.1128.","journal-title":"JAMA Ophthalmol"},{"key":"1495_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/IMCRJ.S225173","volume":"12","author":"T Miyakubo","year":"2019","unstructured":"Miyakubo T, Mukai R, Nakamura K, Matsumoto H, Akiyama H. A case of ipilimumab-induced unusual serous retinal detachment in bilateral eyes. Int Med Case Rep J. 2019;12:355\u201361. https:\/\/doi.org\/10.2147\/IMCRJ.S225173.","journal-title":"Int Med Case Rep J"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01495-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:35:14Z","timestamp":1623108914000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01495-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1495"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01495-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study complied with the tenets of the Declaration of Helsinki. Ethics approval was not required because this was a single case report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained written consent from the patient\u2019s wife to publish this report<b>.<\/b> A copy of the written consent form is available for review by the journal Editor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}